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 Abstract : 240 words 
 
 
Objective: To assess the prevalence of and associated factors with squamous intraepithelial 
lesions and condyloma (HPV-related lesions) in HIV-infected patients. 
Design: Cross-sectional study.  
Setting: Tertiary care university hospital.  
Patients: 516 consecutive outpatients. 
Intervention: Systematic examination for macroscopic HPV-lesions through anoscopy with 
histological confirmation, evaluation of dysplasia and HPV typing. Sexual behaviours were 
assessed through a semi-directive questionnaire. 
Main outcome measures: Perianal and endoanal HPV-lesions with and without histological 
dysplasia. 
Results: Among 473 (92%) examined patients, (200 homosexual men, 123 heterosexual men, 
150 women), 108 (23%) had histologically-confirmed anal HPV-lesions (36%, 15% and 11% 
of the respective populations), including 51 (47%) with only endoanal localisation. Among 
these 108 patients, histological dysplasia of grades I or II and of grade III were noted 
respectively in 59 and 2 patients, invasive endoanal cancer in 1; 3 patients also had high-risk 
oncogenicity HPV without dysplasia. Independent identified associated factors of HPV-
related condyloma were number of incidents of sexual intercourse per month (OR=1.04; 95% 
CI: 1.01-1.06), CD4 cell count below 200 x10
6
 cells/L  (OR=3.22; 95% CI: 1.37-7.60), 
history of anal HPV-lesion (OR=4.57; 95% CI: 2.13-9.81), and receptive anal intercourse 
(OR=2.30; 95% CI: 1.11-4.77). These two latter factors remained associated with histological 
dysplasia (OR=2.82; 95% CI: 1.38-5.76 for history of anal condyloma, and OR=4.29; 95% 
CI: 2.18-8.44 for receptive anal intercourse). 
Conclusions: The high rate of condyloma and histological dysplasia seen in this study argues 
for a systematic screening for these lesions in HIV-infected individuals. 
 
Keywords: HIV, anal canal, Human papillomavirus, anal dysplasia, anal cancer,  condyloma 
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INTRODUCTION 
 
The incidence of epidermoid anal cancer is reported to have increased in recent 
decades and may be even higher among HIV-positive men who have sex with men (MSM) [1-
4]. There is strong evidence that anal squamous intraepithelial lesions (SIL) - the putative 
precursor lesion - and anal cancer are both linked to some Human Papillomavirus (HPV) 
infections [4, 5]. Detection of anal HPV through molecular techniques is frequent in both 
HIV-infected MSM and women [4, 6], and to a lesser extent in HIV-negative individuals. In 
two recent reports, anal HPV was also detected in HIV-infected heterosexual males in the 
absence of anal intercourse [7, 8]. Similarly, detection of anal SIL through anal cytology 
samples is more frequent in HIV-positive MSM than in HIV-negative ones [9], and risk for 
progression from low-grade SIL toward high-grade SIL is higher in HIV-infected MSM than 
in HIV-negative MSM [10]. 
Since the second half of the 90’s, highly active antiviral therapy (HAART) has 
dramatically decreased HIV morbidity and mortality. The effect of HAART on the incidence 
of anal cancer, precursor lesions and HPV prevalence can be complex and results reported in 
the literature are conflicting [11-13]. On the one hand, the induced immune recovery could 
reduce the prevalence of HPV infection, anal SIL and their evolution toward dysplasia; on the 
other hand, the increase in the sexual activity and lengthened survival associated with 
HAART may paradoxically lead to an opposite effect [9, 10, 14]. 
Anal intraepithelial HPV infection may lead to different types of macroscopic lesions, 
depending on HPV types, with non-oncogenic HPV types leading to benign lesions usually 
named condyloma and oncongenic HPV types, such as types 16 and 18, leading to 
intraepithelial dysplasia. As HPV-induced anal dysplasia has been associated with an 
increased risk of anal cancer, it seemed important to us in the HAART era to determine the 
prevalence of these different types of macroscopic HPV-related anal lesions [1, 15]. 
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We report here the results of a systematic screening for macroscopic anal HPV related 
lesions with a systematic search for intraepithelial dysplasia or cancer in a large population of 
HIV-infected individuals. Our objective was to determine the prevalence of these lesions 
(condyloma and intraepithelial dysplasia) in the HAART era in consecutive MSM, women 
and heterosexual men and to identify their risks factors.  
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METHODS  
Patients and Study Design 
Beginning in May 2003 and during a 12-month period, screening for anal macroscopic 
HPV related lesion was systematically proposed by the primary care physician during a 
routine follow-up visit to a sample of HIV-infected outpatients in the infectious diseases units 
of Bichat Claude Bernard University hospital in Paris, France. The sample was composed of 
all consecutive patients consulting any of the medical doctors present during 3 randomly-
determined half-days per week. The 3 selected half-days were modified 3 times during the 
study period to allow for the screening of a representative sample of patients. 
 
Data Collected  
We collected the following data for each patient (whether they accepted screening or 
not): sex, age, geographic origin, risk factors for HIV infection, mean interval since the 
detection of HIV positive serostatus, worst Centers for Disease Control and Prevention stage 
of disease, CD4 cell nadir, CD4 cell count and HIV-RNA level at the time of the consultation 
as well as current antiretroviral therapy. In patients who refused the screening, the reason for 
the refusal was noted (lack of time, anal HPV-related lesion already monitored by a 
proctologist, unwillingness). In patients who accepted the screening, a standardized 
questionnaire was filled out after anal examination by the proctologist. This questionnaire 
asked for information regarding previous sexual transmitted diseases, history of genital and 
anal condyloma including the date and the type of the last treatment, and sexual activities and 
practices (anal sexual intercourse, frequency of acts of sexual intercourse per month, number 
of sexual partners per year, condom use). Men were considered to be homosexual or bisexual 
men if the reported HIV transmission risk factor was homosexuality or if they declared having 
receptive anal intercourse (hereafter referred to as homosexual men). 
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Anal Examination 
Anal examination was performed immediately following the HIV consultation in the 
infectious diseases unit by the same experienced proctologist (internal medicine physician 
with gastroenterology subspecialty training in proctology). The examination consisted in an 
ocular inspection (with and without aceto-white test which is considered to increase the 
visibility of HPV intra-epithelial lesions) of the anal margin (anal area visible before 
anoscopy examination) and an anal canal examination through anoscopy. Acetic acid was 
applied to the total area of anal margin and canal. HPV intra-epithelial lesion was suspected in 
case of either an acetowhite area or a slightly elevated mucosa resembling tumors white to 
pink in color or of exophytic elevated lesions easily distinguishable from normal mucosa. 
Biopsy was systematically performed to confirm the diagnosis of HPV related lesion. In the 
case of lesions found during the screening, patients were asked if they had any related 
discomfort. In males, external genital organs were also examined. 
 
Histological Analysis  
HPV intra-epithelial lesions were diagnosed by two independent observers using 4-
m-thick, paraffin-embedded sections of formalin-fixed tissue and stained with HES. 
Diagnosis was based on hyperpapillomatosis associated with hyperacanthosis and the 
presence of koilocytes. Low grade SIL, also called anal intraepithelial neoplasia of grade I-II 
(AIN 1 and 2) or low grade dysplasia, was defined as thickening of the squamous epithelium 
and slight (lower third) to moderate (lower half) architectural disruption with atypical cells 
but no atypical mitosis. High grade SIL also called anal intraepithelial neoplasia of grade III 
(AIN 3) or high grade dysplasia, was defined as loss of normal stratification of the cells, 
severe architectural disruption, and presence of atypical cytoplasm and nuclear features 
throughout the epithelium, particularly with atypical mitosis. Invasive squamous carcinoma 
was defined as tumor with extensive infiltration of the lamina propria by clusters of tumor 
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cells having deeply invaded the anal wall [1, 16]. Macroscopic HPV related lesions without 
dysplasia are hereafter referred to as “condyloma”. 
 
In situ molecular techniques for detection of HPV 
 In situ hybridization (ISH) was used for HPV screening and typing. For ISH, 
biotinylated and fluorescein isothiocyanate- labeled commercial genomic DNA probes were 
purchased from Argène (Varhiles, France) and Dakopatt (Glostrup, Denmark). ISH was 
performed according to our previously published protocol using probes specific to the various 
types of HPV: 6, 11, 16, 18, 31 and 33 (1). When previous specific ISH were negative, ISH 
was performed using low (HPV 6/11) and high risk (16/18/31/33/35/39/45/51/52/56/58/59/ 
68) probes (Dakopatt). It was amplified with the biotinyl-tyramide complex and the 
diaminobenzidine chromogen (Genpoint kit, Dakopatt).  HPV detected by the high risk probe 
or the specific 16, 18, 31 or 33 probes were considered as being HPV type at high risk for 
oncogenicity. 
 
Statistical Analysis  
Patients were classified into three levels: patients with no HPV related lesions, patients 
with anal condyloma and patients with histological anal dysplasia. Thus, we used a 
polytomous logistic regression model to assess the association between categories of patients 
and characteristics of patients. Characteristics that were related to categories of patients in 
bivariate analysis were kept in the multivariate analysis with stepwise selection of the 
covariables. In bivariate analysis, qualitative variables were compared using chi-squared or 
Fisher’s exact test, when appropriate, and quantitative variables were compared by analysis of 
variance. In multivariate analysis, the "patients with no lesions" category was the reference 
group. A significance level of 0.10 was required to include a variable in the model and a 
significance level of 0.05 was required for a variable to remain in the model. Odds ratios with 
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a 95% confidence interval (CI) were estimated. All statistical analyses were performed with 
SAS software, version 9.1 (SAS institute). 
 
Ethics 
All patients received written information before examination, and the local ethics 
committee approved the study.  
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RESULTS 
Anal examination was proposed to 516 HIV-infected patients, 473 (92%) of whom 
accepted. Among the 43 patients who refused anal examination, 35 were male (11 
homosexual and 24 heterosexual) and 8 female. The reasons for refusal included the 
following: known anal HPV intra-epithelial lesion already monitored by a proctologist (7 
patients); lack of time (13 patients); unwillingness (23 patients). There was no difference in 
epidemiological data, CD4 cell count or nadir, plasmatic HIV-RNA value, CDC stage or 
percentage of HAART-receiving patients between the 473 patients who accepted and the 43 
who refused the screening. The only difference observed was for injection drug addiction 
patients. Among the 43 patients who refused the screening, 10 (23%) were IV-drug addicts 
whereas there were 37 (8%) among the 473 who accepted (p = 0.003). 
The characteristics of the 473 patients who accepted the screening are described in 
Table 1. The median age was 40 years (IQR 35-46); 28% patients were at CDC stage C, 
median CD4 cell count was 454 x10
6
 cells/L (IQR 296-618), and 60% of the patients had 
HIV-RNA below the limit of quantification (50 copies/ml). Twenty-four percent of the 473 
patients reported having unprotected sexual intercourse and 18% of the women reported 
receptive anal intercourse. 
Among the 473 patients, 108 (23 %) had macroscopic HPV-related lesion and 47% of 
them (51/108) had only anal canal lesion (38/200 homosexual men, 8/123 heterosexual men 
and 5/150 women). The proportion of HPV-related lesion was 36.5 % (73/200) among 
homosexual men, 14.6 % (18/123) among heterosexual men and 11.3 % (17/150) among 
women. Among the 108 patients with HPV related lesions, 47 had condyloma and 61 had 
histological dysplasia (13% of the 473 patients) with low grade dysplasia (AIN 1-2) in 59 
patients and high grade dysplasia (AIN 3) in 2 patients. Localisation of dysplasia between the 
anal margin and the anal canal is described in figure 1. The repartition of dysplasia among the 
three populations was as follows: 42/200 homosexual men (21%), 9/123 heterosexual men 
(7.3%) and 10/150 women (6.7%). High-risk oncogenicity HPV types were identified in 90% 
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of the 61 patients with dysplasia; 3 patients also had high-risk oncogenicity HPV without 
dysplasia. One invasive anal carcinoma was detected in one patient.  
Seventy patients (15%) had a previous history of anal condyloma, the last treatment of 
which had been performed on average 8 years ago. Seventy-seven percent of patients with 
anal HPV related lesion had no discomfort. Among the 473 screened patients, screening for 
anal HPV intra-epithelial lesion had been previously proposed to only 10 (2.1 %), of those 9 
were homosexual and 1 was a woman. No patients had previously undergone anal cytology 
sampling. 
Table 2 shows patients characteristics associated with anal condyloma or anal 
histological dysplasia among homo- or bisexual men, heterosexual men and women. Table 3 
shows bivariate analysis of associated factors for anal condyloma and for anal histological 
dysplasia. Multivariate analysis for independent risk factors associated with anal condyloma 
and anal histological dysplasia, compared to patients with no anal lesions is displayed in 
Table 4. The number of incidents of sexual intercourse per month (OR=1.04; 95% CI: 1.01-
1.06), CD4 cell count below 200 x10
6
 cells/L (OR=3.22; 95% CI: 1.37-7.60), history of anal 
HPV related lesion (OR=4.57; 95% CI: 2.13-9.81), and receptive anal intercourse (OR=2.30; 
95% CI: 1.11-4.77), were independently associated with anal condyloma, whereas only 
history of anal HPV related lesion (OR=2.82; 95% CI: 1.38-5.76) and receptive anal 
intercourse (OR=4.29; 95% CI: 2.18-8.44) were associated with anal histological dysplasia. 
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DISCUSSION 
The systematic screening for anal macroscopic HPV related lesions conducted in this 
study on this large HIV-infected population during the HAART era revealed a high 
prevalence of anal condyloma (10%) and histological dysplasia (13%), of which half were 
exclusively endoanal. These findings concern not only the homosexual male population but 
also the heterosexual male population and the female population. 
The comparison of the characteristics of this screened population with those of the 
population who refused the screening in this study shows that they were comparable except 
for the proportion of IV-drug addiction, which was a more frequent HIV transmission risk 
factor in the population of patients who refused the screening. The reason of the refusal in this 
population was essentially due to unwillingness. As the selected sample was randomly 
chosen, we assume that the studied population is representative of the whole population of 
HIV-infected outpatients seen in our hospital. One limitation of our study could be the referral 
bias of a large tertiary-care center. Because the study was conducted at a single center, we 
cannot exclude the possibility that geographic variation in the characteristics of the HIV-
infected patients may have influenced the results. However, the characteristics of the HIV-
infected patients seen in our hospital are comparable to those of patients seen in French 
hospitals based on the comparison of their characteristics using the DMI-2 software, in the 
French Hospital Data base on HIV. 
The relation between anal condyloma considered as a benign lesion and anal 
histological dysplasia is very close as both diseases are linked to HPV infection and probably 
share transmission risk behaviours. A recent cohort study showed an incidence of anal 
intraepithelial neoplasia and anal cancer of 0.1/1000 patient/year in the HIV-infected 
population with anal condyloma [15]. Similarly, Frisch et al, in analysing risk factors for anal 
cancer in women, reported an odds ratio of 9.8 in women with a history of anal condyloma 
[3]. Looking specifically at associated factors of each disease may help understand the 
relation between these two types of anal HPV infection.  
Abramowitz AIDS third revision; manuscript D-05-01251 05_01_07  12 
There is no similar study in the literature performed before or during the HAART era 
to which our study could be compared as regards to the prevalence of histologically proved 
anal HPV infection. Our results could however be analysed in light of the prevalence of anal 
HPV shedding in the homosexual HIV infected men, which has been extensively studied. The 
presence of condyloma and anal histological dysplasia detected in the heterosexual male 
population without any history of anal intercourse, which has never previously been studied, 
is not surprising as, on the one hand, anal HPV shedding has been detected in heterosexual 
men in Piketty et al. study [7, 8], and on the other hand, husbands of women with cervical 
cancer have been found at an increased risk for anal cancer [17]. However, in the study of 
Piketty et al., the heterosexual male population with no history of anal intercourse was 
restricted to male injection drug users and therefore did not include all categories of 
heterosexuals [7]. Interestingly, the increase in the rate of HPV related lesions in HIV-
infected homosexual patients as compared to heterosexual patients found in the present study 
(36.5 % vs 14.6%) is consistent with the 2-fold higher rate of HPV detection reported in 
homosexual men as compared to heterosexual in a previous study (85% versus 46%) [7]. 
The prevalence of anal HPV related lesions (11.3%) in our population of women is 
much higher than that reported in a previous study (1,6%) [18]. The difference could be due 
to different reasons. First, it could be related to the examined anal region. In fact, Conley et al. 
looked only for anal margin localisation without looking for anal canal localisation. However, 
our prevalence remained higher when we did not take into account the 3 % (5/150 women) of 
intra anal condyloma. Another reason may be the experience of the screening doctor. In our 
study, the examinations were performed by a senior proctologist, whereas they were 
performed by gynaecologists in the study of Conley et al. The prevalence we found in our 
study could not be overestimated because condyloma diagnosis in each case was based on 
histological result.  
Multivariate analysis of risk factors associated with on the one hand condyloma and 
on the other hand anal histological dysplasia reveals both common but also distinct 
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characteristics. In fact, neither virological (HIV-RNA) characteristics, CDC stage, geographic 
origins, length of known HIV positive serology, nor use of HAART were associated with the 
presence of anal condyloma or anal histological dysplasia. On the contrary, CD4 cell count 
below 200 x 10
6
 cells/L at the time of the screening was independently associated with the 
presence of condyloma whereas it was not for histological dysplasia. In the literature, there 
are conflicting data concerning the identification of CD4 cell count, CD4 nadir or current use 
of HAART as risk factors for HPV shedding or cytological dysplasia in homosexual men, 
heterosexual male injection drug users [7, 8, 19] and in women [4, 13, 18, 20]. Given our 
results, and given that other authors have studied only anal HPV shedding rather than HPV 
related histological lesions, we can hypothesise that immunity does not play the same role in 
controlling anal HPV shedding, benign anal HPV lesions (condyloma, related to non-
oncogenic HPV) development or anal dysplasia (related to oncogenic HPV) development.   
History of anal condyloma was a strong predictor of the detection of both HPV related 
lesions (anal condyloma and histological dysplasia). Of note is that the time interval between 
the last treatment of previous anal condyloma lesion and the screening was rather long 
(average 8 years) and that the treatment dates back to the pre-HAART period in most patients. 
As the large majority of our patients were receiving HAART and were in virological success, 
we hypothesise that their immunological status improved between these two periods, but this 
improvement was not sufficient to prevent the recurrence of HPV-related lesions. Results are 
similar to those of recent studies in which no effect of HAART on HPV related lesions was 
observed [13, 21]. 
Sexual practices were also independently associated with anal HPV lesions, such as 
the number of incidents of sexual intercourse which has been previously reported to be 
associated with abnormal anal cytologic findings in homosexual men [7]. However, in our 
population, the independent association between anal HPV lesion and the number of incidents 
of sexual intercourse was significant for condyloma whereas it was only a trend for 
histological dysplasia. Receptive anal intercourse was a risk factor both for condyloma and 
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histological dysplasia, which underlines the need to identify these sexual practices in women 
and bisexual men. However, as noted by others, the absence of anal intercourse cannot be 
used to rule out with certainty the presence of anal lesions or to systematically exclude such 
patients from a detection process [4, 7, 8]. 
Histologically proved anal HPV lesions and/or high-risk HPV anal infection are thus 
frequent in this large population of HIV-infected patients including patients previously not 
considered to be at risk for anal cancer. Given their frequency and their potential relation to 
anal neoplasia, systematic screening should be considered. Whether this detection should 
concern the entire HIV-infected population or only those patients at highest risk of HPV-
related lesion has yet to be determined. The screening guidelines could differ between 
homosexual men, heterosexual men and women. These guidelines should also be 
implemented according to a criterion of cost-effectiveness. A pragmatic approach could be 
proposed: in homosexual men, the presence of HPV related lesion with histological sign of 
dysplasia in more than one fifth of patients suggests that this detection should include all 
homosexual HIV-infected men regardless of CD4 cell count or use of antiretrovirals, and 
especially in the case of frequent sexual activity and of history (even long past) of anal HPV 
lesions. In heterosexual men and in women, detection should probably focus on patients with 
a history of HPV-related diseases and previous mentioned at-risk behaviors. This screening 
should also be accompanied by prevention information to help reduce the rate of the at-risk 
behaviors for HPV exposure. 
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Table 1: Characteristics of 473 HIV-infected patients who accepted the screening for anal HPV-related lesions.  
 
Total HIV population 
n = 473 
Homo or bisexual men 
n = 200 (42%) 
Heterosexual men 
n = 123 (26%) 
Women 
n = 150 (32%) 
P-value 
Median age (IQR)  40 (35-46) 41 (36-46) 42 (37-48) 37 (33-42) < 0.0001 
Geographic origins: 
Europe, n (%) 
North Africa, n (%) 
Black Africa, n (%) 
West Indies, n (%) 
South America, n (%) 
Asia, n (%) 
 
229 (48.4 %) 
46 (9.7 %) 
149 (31.5 %) 
22 (4.6 %) 
16 (3.4 %) 
11 (2.3 %) 
 
161 (80.5 %) 
6 (3.0 %) 
6 (3.0 %) 
11 (5.5 %) 
13 (6.5 %) 
3 (1.5 %) 
 
39 (31.7 %) 
21 (17.1 %) 
51 (41.5 %) 
6 (4.9 %) 
0 
6 (4.9 %) 
 
29 (19.3 %) 
19 (12.7 %) 
92 (61.3 %) 
5 (3.3 %) 
3 (2.0 %) 
2 (1.3 %) 
 
 
 
< 0.0001 
 
HIV transmission risk factors*: 
Homosexuality, n (%) 
Injection drug user, n (%) 
Heterosexuality, n (%) 
Blood transfusion, n (%) 
Unknown, n (%) 
 
192 (40.6 %) 
37 (7.8 %) 
215 (45.4 %) 
7 (1.5 %) 
28 (5.9 %) 
 
- 
2 (1.0 %) 
- 
0 
1 (0.5 %) 
 
- 
21 (17.1 %) 
- 
3 (2.4 %) 
17 (13.8 %) 
 
- 
14 (9.3 %) 
- 
4 (2.7 %) 
10 (6.7 %) 
 
 
< 0.0001 
 
0.0309 
< 0.0001 
Median length for known positive HIV serology, year (IQR) 7.2 (2.7-12.3) 9.5 (4.8-13.4) 6.1 (2.2-11.7) 4.0 (1.9-9.7) < 0.0001 
CDC stage:   A, n (%): 
         B, n (%): 
         C, n (%): 
265 (56.0 %) 
77 (16.3 %) 
131 (28 %) 
108 (54.0 %) 
37 (18.5 %) 
55 (27 %) 
63 (51.2 %) 
18 (14.6 %) 
42 (34 %) 
94 (62.7 %) 
22 (14.7 %) 
34 (23 %) 
 
0.1914 
Median nadir of CD4+ cell count (IQR), x 106 cells/L 196 (68-318) 231 (79-338) 127 (62-260) 203 (90-327) 0.0411 
Abramowitz AIDS third revision; manuscript D-05-01251 05_01_07  20 
Table 1: Characteristics of 473 HIV-infected patients who accepted the screening for anal HPV-related lesions.  
 
Total HIV population 
n = 473 
Homo or bisexual men 
n = 200 (42%) 
Heterosexual men 
n = 123 (26%) 
Women 
n = 150 (32%) 
P-value 
Patients receiving antiretroviral therapy,  n (%) 363 (77 %) 167 (83 %) 96 (78 %) 100 (67 %) 0.0010 
Median CD4+ cell count (IQR), x 106 cells/L 454 (296-618) 533 (365-707) 380 (220-553) 410 (288-584) < 0.0001 
Patients with HIV-RNA level < 50 log copies/ml, n (%) 284 (60 %) 126 (63 %) 75 (61 %) 83 (55 %) 0.3135 
Median plasma HIV-RNA level (IQR), log copies/ml (among patients 
with HIV-RNA level > 50 log copies/ml) 
3.9 (2.6-4.8) 3.6 (2.4-4.9) 4.1 (2.8-4.8) 3.9 (2.9-4.8) 0.6080 
History of gonorrhoea, n (%) 
History of syphilis, n (%) 
141 (30 %) 
76 (16 %) 
89 (44 %) 
56 (28 %) 
40 (33 %) 
10 (8 %) 
12 (8 %) 
10 (7 %) 
< 0.0001 
< 0.0001 
Sexual practice†: 
Median number of acts of sexual intercourse during a month,  (IQR) 
Median number of sexual partners during a year, n (IQR) 
Unprotected sexual intercourse n (%) 
Receptive anal intercourse, n (%)  
 
3 (0-8) 
1 (0-2) 
104/432 (24 %) 
227/473 (48%) 
 
 5 (1-10) 
2 (1-10) 
51 (28 %) 
200 (100%) 
 
3 (0-8) 
1 (1-1) 
16 (15 %) 
0 (0%) 
 
1 (0-4) 
1 (0-1) 
37 (28 %) 
27 (18 %) 
 
< 0.0001 
< 0.0001 
0.0329 
 
IQR : Interquartil range (25-75%) 
*
 Six patients had two HIV-transmission risk factors (4 with heterosexuality and injection drug user and 2 with heterosexuality and blood transfusion). 
† Information obtained in 91 % patients. 
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Table 2: Patients characteristics according to the detection of anal condyloma or anal histological dysplasia among homo or bisexual men, heterosexual men 
and women in the 473 HIV-infected patients who accepted the screening. 
 Homo or bisexual men Heterosexual men Women 
 
No lesion 
n=127 
Anal condyloma 
n=31 
Anal Dysplasia 
n=42 
No lesion 
n=105 
Anal condyloma 
n=9 
Anal Dysplasia 
n=9 
No lesion 
n=133 
Anal condyloma 
n=7 
Anal Dysplasia 
n=10 
Geographic origins 
Europe 
North Africa 
Black Africa 
Other 
 
105/127(83%) 
2/127 (2%) 
5/127 (4%) 
15/127 (12%) 
 
25/31 (81%) 
1/31 (3%) 
0/31 (0%) 
5/31 (16%) 
 
31/42 (74%) 
3/42 (7%) 
 1/42 (2%) 
7/42 (17%) 
 
30/105 (29%) 
15/105 (14%) 
49/105 (47%) 
11/105 (10%) 
 
3/9 (33%) 
3/9 (33%) 
2/9 (22%) 
1/9 (11%) 
 
6/9 (67%) 
3/9 (33%)      
0/9 (0%) 
0/9 (0%) 
 
25/133 (19%) 
18/133 (14%) 
83/133 (62%) 
7/133 (5%) 
 
1/7 (14%) 
1/7 (14%) 
3/7 (43%) 
2/7 (29%) 
 
3/10 (30%) 
0/10 (0%)       
6/10 (60%) 
1/10 (10%) 
Positive HIV serology > 10 years 
>5 and < 10 years 
< 5 years 
59/127 (46%) 
39/127 (31%) 
29/127 (23%) 
16/31 (52%) 
4/31 (13%) 
11/31 (35%) 
20/42 (48%) 
9/42 (21%) 
13/42 (31%) 
32/105 (30%) 
26/105 (25%) 
47/105 (45%) 
2/9 (22%) 
4/9 (44%) 
3/9 (33%) 
4/9 (44%) 
3/9 (33%) 
2/9 (22%) 
31/133 (23%) 
26/133 (20%) 
76/133 (57%) 
3/7 (43%) 
1/7 (14%) 
3/7 (43%) 
3/10 (30%) 
    2/10 (20%) 
5/10 (50%) 
Previous AIDS-defining event 39/127 (31%) 9/31 (29%) 7/42 (17%) 33/105 (31%) 5/9 (56%) 4/9 (44 %) 28/133 (21%) 2/7 (29%) 4/10 (40%) 
Nadir CD4+ cell count  < 200 x106 cells/L  
 
55/126 (44%) 
 
 
14/31 (45%) 
 
 
17/41 (41%) 
 
 
65/104 (63%) 
 
 
7/9 (78%) 
 
 
7/9 (78%) 
 
 
63/133 (47%) 
 
 
6/7 (86%) 
 
 
6/10 (60%) 
 
Patient receiving anti-retroviral therapy 107/127 (84%) 26/31 (84%) 34/42 (81%) 84/105 (80%) 5/9 (56%) 7/9 (78%) 91/133 (68%) 5/7 (71%) 4/10 (40%) 
CD4+ cell count    < 200  x106 cells/L   7/127 (6%) 3/31 (10%) 4/42 (10%) 17/105 (16%) 6/9 (67%) 2/9 (22%) 16/133 (12%) 3/7 (43%) 2/10 (20%) 
Patients with HIV-RNA < 50 log copies/ml 81/126 (64%) 16/31 (52%) 29/42 (69%) 66/105 (63%) 5/9 (56%) 4/9 (44%) 77/133 (58%) 3/7 (43%) 3/10 (30%) 
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Table 2: Patients characteristics according to the detection of anal condyloma or anal histological dysplasia among homo or bisexual men, heterosexual men 
and women in the 473 HIV-infected patients who accepted the screening. 
 Homo or bisexual men Heterosexual men Women 
 
No lesion 
n=127 
Anal condyloma 
n=31 
Anal Dysplasia 
n=42 
No lesion 
n=105 
Anal condyloma 
n=9 
Anal Dysplasia 
n=9 
No lesion 
n=133 
Anal condyloma 
n=7 
Anal Dysplasia 
n=10 
History of  anal condyloma 29/127 (23%) 11/31 (35%) 16/42 (38%) 1/104 (1%) 3/9 (33%) 0/9 (0%) 5/133 (4%) 2/7 (29%) 3/10 (30%) 
History of genital HPV related lesion 12/127 (9%) 2/31 (6%) 2/42 (5%) 1/104 (1%) 2/9 (22%) 1/9 (11%) 13/133 (10%) 1/7 (14%) 5/10 (50%) 
History of gonorrhoea or syphilis 75/127 (59%) 13/31 (42%) 20/42 (48%) 36/105 (34%) 4/9 (44%) 2/9 (22%) 15/133 (11%) 2/7 (29%) 0/10 (0%) 
Median number of acts of sexual 
intercourse during a month (IQR) 
4 (1-9) 4 (1-15) 6 (2-10) 3 (0-7) 8 (1-12) 1 (0-5) 1 (0-4) 3 (0-20)) 0.5 (0-2) 
Median number of sexual partners during a 
year (IQR) 
1 (1-10) 5 (1-50) 4 (1-10) 1 (1-1) 1 (1-1) 1 (1-1) 1 (0-1) 1 (0-1) 1 (0-1) 
Unprotected sexual intercourse  34/118 (29%) 7/31 (23%) 10 (38 (26%) 10/97 (10%) 4/8 (50%) 3/8 (37%) 33/119 (28%) 2/5 (40%) 1/8 (12%) 
Receptive anal intercourse 
127/127 
(100%) 
31/31 (100%) 42/42 (100%) 0 0 0 20/122 (16%) 2/5 (40%) 5/8 (62%) 
 
Note: Number of patients (% or IQR); IQR Interquartil range (25%-75%) 
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Table 3: Bivariate analysis among 3 categories of patients : without anal lesion, with anal condyloma and with histological anal dysplasia. 
 
 
Patients with 
no anal lesion 
 
Patients with 
 anal condyloma 
 
Patients with  
histological anal dysplasia 
 P Value 
Geographic origins 
Europe 
North Africa 
Black Africa 
    Other 
 
160/365 (44%) 
35/365 (10%) 
137/365 (37%) 
33/365 (9%) 
 
 
29/47 (61%) 
5/47 (11%) 
5/47 (11%) 
8/47 (17%) 
 
 
40/61 (66%) 
6/61 (10%) 
7/61 (11%) 
8/61 (13%) 
 
 
 
< 0.0001 
Positive HIV serology  
> 10 years 
>5 and < 10 years 
< 5 years 
 
122/365 (33%) 
91/365 (25%) 
152/365 (42%) 
 
 
21/47 (45%) 
9/47 (19%) 
17/47 (36%) 
 
 
27/61 (44%) 
14/61 (23%) 
20/61 (33%) 
 
 
 
0.3255 
Previous AIDS-defining event 100/365 (27%)  16/47 (34%)  15/61 (25%)  0.5423 
Nadir CD4+ cell count < 200  x106 cells/L       
 
183/363 (50%) 
 
 
27/47 (57%) 
 
 
30/60 (50% 
 0.6521 
Patient receiving anti-retroviral therapy 
 
282/365 (77%) 
 
 
36/47 (77%) 
 
 
45/61 (74%) 
 
 
0.8364 
CD4+ cell count   < 200  x106 cells/L      40/365 (11%)  12/46 (26%)  8/61 (13%)  0.0184 
Patients with HIV-RNA level < 50 log copies/ml 224/364 (62%)  24/47 (51%)  36/61 (59%)  0.3782 
History of anal condyloma 35/364 (10%)  16/47 (34%)  19/61 (31%)  < 0.0001 
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Patients with 
no anal lesion 
 
Patients with 
 anal condyloma 
 
Patients with  
histological anal dysplasia 
 P Value 
History of genital HPV- related lesion 26/364 (7%)  5/47 (11%)  8/61 (13%)  0.2409 
History of gonorrhoea or syphilis 126/365 (35%)  19/47 (40%)  22/61 (36%)  0.7213 
Median number of acts of sexual intercourse during a month (IQR) 2 (0-8)  4 (1-12)  4 (1-10)  < 0.0001 
Median number of sexual partners during a year (IQR) 1 (0-1)  1 (1-10)  1 (1-10)  < 0.0026 
Unprotected sexual intercourse  77/334 (23%)  13/44 (30%)  14/54 (26%)  0.6029 
Receptive anal intercourse 112/339 (33%)  27/44 (61%)  39/54 (72%)  < 0.0001 
Homo or bisexual men 
Heterosexual men 
Women 
127/365 (35%) 
105/365 (29%) 
133/365 (36%) 
 
31/47 (66%) 
9/47 (19%) 
7/47 (15%) 
 
42/61 (69%) 
9/61 (15%) 
10/61 (16%) 
 
 
< 0.0001 
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Table 4: Associated factors for anal condyloma and anal histological dysplasia in 473 HIV-infected individuals (Multivariate analysis). 
 
  
Anal condyloma 
 
Histological anal dysplasia 
  Odds Ratio
*
 
(95% confidence interval) 
P Value  
Odds Ratio
*
  
(95% confidence interval) 
 P Value 
CD4+ cell count  < 200 x10
6
 cells/L (versus > 200)  3.22 (1.37-7.60) 0.007  1.74 (0.70-4.38) 0.235 
Receptive anal intercourse (yes versus no)  2.30 (1.11-4.77) 0.026  4.29 (2.18-8.44) < 0.001 
History of anal condyloma (yes versus no)  4.57 (2.13-9.81)  < 0.001  2.82 (1.38-5.76)  0.004 
Number of incidents of sexual intercourse per month   
(for each additional incident) 
 1.04 (1.01-1.06)  0.003  1.02 (0.99-1.04) 0.144 
*
Odds ratios (from polytomous logistic regression) for “Anal condyloma” and “Histological anal dysplasia” are relative to the reference group (“No anal lesions”) 
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 Figure 1:  
 
AIN: anal intraepithelial neoplasia of grade I-II (AIN 1 and 2) or Low grade dysplasia 
AIN 3: anal intraepithelial neoplasia of grade III or High grade dysplasia 
 
 
A na l m argin (n= 27)
- A IN 1  =  22
- A IN  2 =  5
- A IN  3 =  0
A na l canal (n= 47)
- A IN 1  =  40
- A IN  2 =  5
- A IN  3 =  2
P a tients w ith  histo log ica l dysp lasia
n  = 61  (56 % )
P a tients w ith  anal condylom a
n  = 47 (44%)
P atients w ith  HP V-related lesion
n  = 108
P atient with ana l epiderm oïd ca rcinom a
n  =  1
H IV-in fected  pa tien ts
n  = 473
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Figures’ legends: 
 
 
 
Figure 1: Number of patients with anal intraepithelial neoplasia according to the localisation 
of the dysplasia on anal margin or on anal canal in the 473 HIV-infected patients who 
accepted the screening. 
  
